Streetbeat News

Revenues

EXR

Extra Space Storage (NYSE:EXR) has significantly outperformed the market over the past 15 years, with an annualized return of 20.19%. A $100 investment in EXR 15 years ago would now be worth $1,604.05, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 2:00 pm

JPM

SPY

JP Morgan's CFO has stated that U.S. consumer spending remains solid and consistent, which could indicate a stable economic environment.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 1:14 pm

BP

DFRA

BP has issued a warning about weaker refining margins and higher debt in its updated third-quarter guidance. The company expects stable upstream production but anticipates unfavorable impacts in oil production and operations. Weaker refining margins are expected to negatively impact results by $0.4 billion to $0.6 billion, and BP projects higher net debt by the end of the quarter.

Portfolio Pulse from Lekha Gupta

October 11, 2024 | 1:12 pm

JPM

JP Morgan projects its FY2024 net interest income to be around $92.5 billion, with a Q3 YTD of $69.6 billion implying a Q4 income of approximately $22.9 billion. Excluding markets, the FY24 net interest income is expected to be $91.5 billion. The FY24 adjusted expense is also projected at $91.5 billion.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 1:03 pm

MIRM

Mirum Pharmaceuticals (NASDAQ:MIRM) has been analyzed by five analysts, with ratings ranging from bullish to somewhat bullish. The average 12-month price target is $60.4, up 6.71% from the previous target. Analysts have raised their ratings and price targets, reflecting positive sentiment. Mirum's revenue growth and market capitalization are strong, but it faces challenges with debt management and return on equity.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 1:01 pm

STRO

Sutro Biopharma (NASDAQ:STRO) has been analyzed by five analysts, showing a range of opinions from bullish to bearish. The average 12-month price target is $13.6, down 4.23% from the previous $14.20. Analysts have maintained or lowered their ratings, with price targets ranging from $12.00 to $17.00. Sutro Biopharma is a clinical-stage company focused on developing biopharmaceutical products, with significant revenue growth but challenges in ROE.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 1:00 pm

SQM

Sociedad Quimica Y Minera (NYSE:SQM) has seen a negative shift in analyst sentiment, with a 20.69% decrease in average price target. Analysts have adjusted their ratings and price targets, reflecting challenges in revenue growth and market conditions. Despite these challenges, SQM maintains strong net margins and effective debt management.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 1:00 pm

JPM

JP Morgan's CFO announced that the bank expects its net interest income, excluding markets, to reach $87 billion by 2025. This projection was shared during a media call.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 12:58 pm

JPM

JPMorgan's CFO announced that the bank expects its net interest income, excluding markets, to reach $87 billion by 2025. This projection was shared during an analyst call.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 12:56 pm

SPAI

Safe Pro Group Inc.'s subsidiary, Airborne Response, is deploying drone teams to assist in recovery efforts in Florida after Hurricane Milton. They are supporting power restoration for 2.4 million people and have secured a new contract with a major municipal utility.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 12:42 pm